15 April 2008 - Roche gains access to important oncology target with potential for treating major cancers such as breast and lung; first drug candidate in phase I clinical testing- Second research programme centred on potential target in inflammatory indications such as rheumatoid arthritis
Roche announced today that it will acquire Piramed Limited, a privately-owned UK company focusing on therapeutics targeting PI3-kinase (PI3-K). The PI3-K pathway is known to play an important role in disease progression and in resistance to chemotherapeutics in cancer cells.
Pre-clinical studies have demonstrated the activity of PI3-K inhibitors in a broad range of tumours such as breast and lung cancer, as well as their potential importance in treating inflammatory diseases such as rheumatoid arthritis... Roche's Press Release - [PDF] Piramed's Press Release -
